Allogene Therapeutics (ALLO) Financials

$1.18 +0.04 (+3.51%)

Closing price 04:00 PM Eastern

Extended Trading

$1.18 0.00 (0.00%)

As of 07:55 PM Eastern

Annual Income Statements for Allogene Therapeutics

This table shows Allogene Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-258	-327	-340
Consolidated Net Income / (Loss)	-258	-327	-340
Net Income / (Loss) Continuing Operations	-258	-327	-340
Total Pre-Tax Income	-257	-327	-340
Total Operating Income	-273	-328	-336
Total Gross Profit	0.02	0.10	0.16
Total Revenue	0.02	0.10	0.16
Operating Revenue	0.02	0.10	0.16
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	273	328	336
Selling, General & Admin Expense	65	72	79
Research & Development Expense	192	243	256
Impairment Charge	16	13	0.00
Total Other Income / (Expense), net	16	0.47	-4.88
Interest Expense	0.18	0.00	-
Interest & Investment Income	20	18	4.57
Other Income / (Expense), net	-3.92	-18	-9.44
Income Tax Expense	0.44	0.00	-
Basic Earnings per Share	($1.32)	($2.09)	($2.38)
Weighted Average Basic Shares Outstanding	194.81M	156.93M	143.15M
Diluted Earnings per Share	($1.32)	($2.09)	($2.38)
Weighted Average Diluted Shares Outstanding	194.81M	156.93M	143.15M
Weighted Average Basic & Diluted Shares Outstanding	217.26M	169.09M	144.50M
Cash Dividends to Common per Share	$0.00	$0.00	$0.00

This table shows Allogene Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-60	-66	-66	-65	-86	-62	-79	-100	-103	-83
Consolidated Net Income / (Loss)	-60	-66	-66	-65	-86	-62	-79	-100	-103	-83
Net Income / (Loss) Continuing Operations	-60	-66	-66	-65	-86	-62	-79	-100	-103	-83
Total Pre-Tax Income	-59	-66	-66	-65	-86	-62	-79	-100	-103	-83
Total Operating Income	-60	-72	-71	-70	-85	-63	-81	-99	-96	-82
Total Operating Expenses	60	72	71	70	85	63	81	99	96	83
Selling, General & Admin Expense	16	16	16	17	17	17	19	19	21	19
Research & Development Expense	45	45	50	52	55	46	62	80	75	64
Total Other Income / (Expense), net	0.99	5.48	5.07	4.50	-0.67	0.71	1.31	-0.88	-6.17	-0.66
Other Income / (Expense), net	-7.39	-1.12	0.09	4.50	-8.99	-5.50	-2.47	-0.88	-9.42	-1.66
Basic Earnings per Share	($0.27)	($0.32)	($0.35)	($0.38)	($0.49)	($0.37)	($0.54)	($0.69)	($0.72)	($0.58)
Weighted Average Basic Shares Outstanding	194.81M	209.19M	190.03M	169.13M	156.93M	167.65M	146.80M	144.56M	143.15M	143.66M
Diluted Earnings per Share	($0.27)	($0.32)	($0.35)	($0.38)	($0.49)	($0.37)	($0.54)	($0.69)	($0.72)	($0.58)
Weighted Average Diluted Shares Outstanding	194.81M	209.19M	190.03M	169.13M	156.93M	167.65M	146.80M	144.56M	143.15M	143.66M
Weighted Average Basic & Diluted Shares Outstanding	217.26M	209.67M	209.11M	170.85M	169.09M	168.28M	167.63M	145.84M	144.50M	144.21M

This table details how cash moves in and out of Allogene Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-7.94	21	-111
Net Cash From Operating Activities	-200	-238	-221
Net Cash From Continuing Operating Activities	-200	-238	-221
Net Income / (Loss) Continuing Operations	-258	-327	-340
Consolidated Net Income / (Loss)	-258	-327	-340
Depreciation Expense	14	14	14
Non-Cash Adjustments To Reconcile Net Income	62	91	102
Changes in Operating Assets and Liabilities, net	-18	-15	3.90
Net Cash From Investing Activities	76	163	106
Net Cash From Continuing Investing Activities	76	163	106
Purchase of Property, Plant & Equipment	-0.69	-1.52	-5.19
Purchase of Investments	-361	-439	-248
Sale and/or Maturity of Investments	438	603	359
Net Cash From Financing Activities	117	96	2.95
Net Cash From Continuing Financing Activities	117	96	2.95
Issuance of Common Equity	114	96	2.95
Other Financing Activities, net	2.28	0.00	-

This table details how cash moves in and out of Allogene Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	24	-119	120	-32	14	-86	45	48	-12	-22
Net Cash From Operating Activities	-37	-44	-64	-56	-54	-56	-62	-67	-62	-48
Net Cash From Continuing Operating Activities	-37	-44	-64	-56	-54	-56	-62	-67	-62	-48
Net Income / (Loss) Continuing Operations	-60	-66	-66	-65	-86	-62	-79	-100	-103	-83
Consolidated Net Income / (Loss)	-60	-66	-66	-65	-86	-62	-79	-100	-103	-83
Depreciation Expense	3.23	3.21	3.64	3.56	3.48	3.57	3.64	3.51	3.07	3.86
Non-Cash Adjustments To Reconcile Net Income	13	23	16	9.99	28	22	18	22	26	24
Changes in Operating Assets and Liabilities, net	7.05	-4.35	-17	-4.44	0.93	-19	-4.36	7.42	11	7.79
Net Cash From Investing Activities	55	-76	75	22	67	-34	17	113	50	25
Net Cash From Continuing Investing Activities	55	-76	75	22	67	-34	17	113	50	25
Purchase of Property, Plant & Equipment	-0.26	-0.43	-	-0.01	-0.18	-0.01	-0.29	-1.04	-1.69	-0.22
Purchase of Investments	-47	-191	-43	-81	-69	-199	-135	-35	-48	-49
Sale and/or Maturity of Investments	102	115	117	103	136	165	153	149	99	75
Net Cash From Financing Activities	5.74	0.68	109	1.65	0.16	4.29	90	1.73	0.05	1.07
Net Cash From Continuing Financing Activities	5.74	0.68	109	1.65	0.16	4.29	90	1.73	0.05	1.07
Issuance of Common Equity	5.74	0.68	106	1.65	0.16	4.29	90	1.73	0.05	1.07

This table presents Allogene Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	549	643	822
Total Current Assets	303	459	529
Cash & Equivalents	75	83	62
Short-Term Investments	217	366	455
Prepaid Expenses	11	10	12
Plant, Property, & Equipment, net	86	99	113
Total Noncurrent Assets	159	84	180
Long-Term Investments	81	3.65	76
Other Noncurrent Operating Assets	79	81	103
Total Liabilities & Shareholders' Equity	549	643	822
Total Liabilities	127	131	155
Total Current Liabilities	36	37	54
Accounts Payable	5.39	5.90	14
Accrued Expenses	30	31	40
Total Noncurrent Liabilities	91	94	101
Other Noncurrent Operating Liabilities	91	94	101
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	422	512	667
Total Preferred & Common Equity	422	512	667
Preferred Stock	0.00	0.00	0.00
Total Common Equity	422	512	667
Common Stock	2,242	2,075	1,912
Retained Earnings	-1,820	-1,562	-1,235
Accumulated Other Comprehensive Income / (Loss)	-0.09	-0.96	-9.93

This table presents Allogene Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	589	647	586	712	771	747	888
Total Current Assets	304	457	395	473	502	481	569
Cash & Equivalents	51	171	51	69	155	110	74
Short-Term Investments	240	274	334	396	337	361	478
Prepaid Expenses	13	12	11	7.95	10	10	17
Plant, Property, & Equipment, net	89	92	96	103	106	110	114
Total Noncurrent Assets	196	98	95	136	162	156	204
Long-Term Investments	112	1.13	15	38	62	54	99
Other Noncurrent Operating Assets	84	97	80	99	100	102	105
Total Liabilities & Shareholders' Equity	589	647	586	712	771	747	888
Total Liabilities	125	132	125	129	148	155	148
Total Current Liabilities	33	37	31	38	55	60	49
Accounts Payable	5.51	13	5.78	6.21	10	15	11
Accrued Expenses	27	24	25	31	44	45	37
Total Noncurrent Liabilities	93	95	94	92	93	95	99
Other Noncurrent Operating Liabilities	93	95	94	92	93	95	99
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	464	515	461	583	623	592	740
Total Preferred & Common Equity	464	515	461	583	623	592	740
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	464	515	461	583	623	592	740
Common Stock	2,223	2,209	2,090	2,060	2,039	1,933	1,894
Retained Earnings	-1,760	-1,694	-1,627	-1,474	-1,413	-1,335	-1,141
Accumulated Other Comprehensive Income / (Loss)	0.16	-0.78	-0.93	-2.41	-3.85	-5.93	-13

This table displays calculated financial ratios and metrics derived from Allogene Therapeutics' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	-76.84%	-39.10%	-99.86%
EBITDA Growth	20.49%	-0.21%	-90.80%
EBIT Growth	19.81%	-0.17%	-87.73%
NOPAT Growth	16.64%	2.32%	-86.21%
Net Income Growth	21.29%	3.86%	-86.99%
EPS Growth	36.84%	12.18%	-77.61%
Operating Cash Flow Growth	15.75%	-7.81%	-19.32%
Free Cash Flow Firm Growth	16.57%	2.80%	-32.49%
Invested Capital Growth	-18.13%	-18.06%	-14.53%
Revenue Q/Q Growth	-48.84%	-43.79%	-99.79%
EBITDA Q/Q Growth	8.98%	3.55%	-49.03%
EBIT Q/Q Growth	8.65%	3.30%	-45.34%
NOPAT Q/Q Growth	8.27%	3.35%	-41.36%
Net Income Q/Q Growth	9.12%	4.90%	-43.21%
EPS Q/Q Growth	14.29%	9.91%	-44.24%
Operating Cash Flow Q/Q Growth	7.83%	3.41%	-8.17%
Free Cash Flow Firm Q/Q Growth	4.45%	5.52%	-35.30%
Invested Capital Q/Q Growth	-18.77%	-25.19%	-17.48%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-1,197,636.36%	-348,813.68%	-211,977.56%
Operating Margin	-1,241,813.64%	-344,986.32%	-215,087.18%
EBIT Margin	-1,259,631.82%	-363,760.00%	-221,141.03%
Profit (Net Income) Margin	-1,170,863.64%	-344,489.47%	-218,214.10%
Tax Burden Percent	100.17%	100.00%	100.00%
Interest Burden Percent	92.79%	94.70%	98.68%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-351.15%	-345.03%	-296.16%
ROIC Less NNEP Spread (ROIC-NNEP)	-335.08%	-326.32%	-281.43%
Return on Net Nonoperating Assets (RNNOA)	296.02%	289.52%	253.40%
Return on Equity (ROE)	-55.13%	-55.51%	-42.76%
Cash Return on Invested Capital (CROIC)	-331.21%	-325.17%	-280.49%
Operating Return on Assets (OROA)	-46.51%	-47.20%	-36.85%
Return on Assets (ROA)	-43.24%	-44.70%	-36.36%
Return on Common Equity (ROCE)	-55.13%	-55.51%	-42.76%
Return on Equity Simple (ROE_SIMPLE)	-61.01%	-63.89%	-51.05%
Net Operating Profit after Tax (NOPAT)	-191	-229	-235
NOPAT Margin	-869,269.55%	-241,490.42%	-150,561.03%
Net Nonoperating Expense Percent (NNEP)	-16.08%	-18.71%	-14.73%
Return On Investment Capital (ROIC_SIMPLE)	-45.30%	-44.79%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	296,386.36%	75,445.26%	50,836.54%
R&D to Revenue	874,086.36%	255,698.95%	164,350.64%
Operating Expenses to Revenue	1,241,913.64%	345,086.32%	215,187.18%
Earnings before Interest and Taxes (EBIT)	-277	-346	-345
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-263	-331	-331
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.06	1.05	1.36
Price to Tangible Book Value (P/TBV)	1.06	1.05	1.36
Price to Revenue (P/Rev)	20,300.07	5,685.98	5,814.63
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.50	1.47	4.29
Enterprise Value to Revenue (EV/Rev)	3,338.75	924.49	2,008.29
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.88	-0.89	-0.90
Leverage Ratio	1.28	1.24	1.18
Compound Leverage Factor	1.18	1.18	1.16
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	-3.61	-1.91	0.72
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	8.54	12.38	9.84
Quick Ratio	8.23	12.10	9.63
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-180	-216	-222
Operating Cash Flow to CapEx	-28,861.67%	-15,681.60%	-4,248.10%
Free Cash Flow to Firm to Interest Expense	-996.57	0.00	0.00
Operating Cash Flow to Interest Expense	-1,106.63	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-1,110.46	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	49	60	73
Invested Capital Turnover	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-11	-13	-12
Enterprise Value (EV)	73	88	313
Market Capitalization	447	540	907
Book Value per Share	$2.01	$3.04	$4.62
Tangible Book Value per Share	$2.01	$3.04	$4.62
Total Capital	422	512	667
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-373	-452	-594
Capital Expenditures (CapEx)	0.69	1.52	5.19
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-25	-27	-42
Debt-free Net Working Capital (DFNWC)	268	422	475
Net Working Capital (NWC)	268	422	475
Net Nonoperating Expense (NNE)	66	98	106
Net Nonoperating Obligations (NNO)	-373	-452	-594
Total Depreciation and Amortization (D&A)	14	14	14
Debt-free, Cash-free Net Working Capital to Revenue	-111,877.27%	-28,064.21%	-27,066.67%
Debt-free Net Working Capital to Revenue	1,217,559.09%	444,248.42%	304,548.72%
Net Working Capital to Revenue	1,217,559.09%	444,248.42%	304,548.72%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($1.32)	($2.09)	$0.00
Adjusted Weighted Average Basic Shares Outstanding	194.81M	156.93M	0.00
Adjusted Diluted Earnings per Share	($1.32)	($2.09)	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	194.81M	156.93M	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	217.26M	169.09M	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-180	-220	-235
Normalized NOPAT Margin	-819,260.91%	-231,730.95%	-150,561.03%
Pre Tax Income Margin	-1,168,850.00%	-344,489.47%	-218,214.10%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-1,531.04	0.00	0.00
NOPAT to Interest Expense	-1,056.57	0.00	0.00
EBIT Less CapEx to Interest Expense	-1,534.88	0.00	0.00
NOPAT Less CapEx to Interest Expense	-1,060.41	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Allogene Therapeutics' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	-100.00%	-100.00%	-26.67%	-77.89%	0.00%	0.00%	-50.82%	-99.87%	0.00%
EBITDA Growth	28.67%	-7.35%	14.70%	36.30%	11.85%	19.14%	-11.12%	-26.66%	-1,827.90%	-6.57%
EBIT Growth	27.87%	-6.43%	14.05%	34.98%	11.12%	18.61%	-10.53%	-25.19%	-6,298.95%	-8.34%
NOPAT Growth	28.93%	-13.93%	11.31%	29.86%	11.77%	23.63%	-5.15%	-23.88%	-4,053.32%	-6.20%
Net Income Growth	30.12%	-6.43%	16.25%	34.98%	16.42%	25.09%	-5.94%	-25.19%	-119,436.05%	-6.35%
EPS Growth	44.90%	13.51%	35.19%	44.93%	31.94%	36.21%	-3.85%	-23.21%	-7,300.00%	-1.75%
Operating Cash Flow Growth	31.67%	20.56%	-2.80%	16.12%	13.51%	-16.53%	-45.44%	2.34%	-36.67%	2.50%
Free Cash Flow Firm Growth	32.11%	14.16%	-105.77%	-50.01%	15.83%	36.46%	60.14%	63.14%	-37.57%	29.56%
Invested Capital Growth	-18.13%	-24.60%	1.21%	-8.55%	-18.06%	-9.61%	-31.64%	-37.78%	-14.53%	-1.93%
Revenue Q/Q Growth	0.00%	0.00%	-100.00%	-48.84%	-4.55%	0.00%	-26.67%	-68.42%	0.00%	0.00%
EBITDA Q/Q Growth	7.24%	-2.94%	-10.18%	32.92%	-39.59%	18.20%	17.72%	6.18%	-28.05%	-12.41%
EBIT Q/Q Growth	6.89%	-2.18%	-9.76%	31.63%	-37.39%	17.49%	16.96%	5.58%	-25.82%	-12.05%
NOPAT Q/Q Growth	15.72%	-0.48%	-2.77%	18.36%	-35.10%	21.78%	18.72%	-2.73%	-16.94%	-7.70%
Net Income Q/Q Growth	9.58%	0.10%	-2.09%	25.07%	-37.71%	21.39%	20.74%	2.59%	-23.43%	-11.18%
EPS Q/Q Growth	15.63%	8.57%	7.89%	22.45%	-32.43%	31.48%	21.74%	4.17%	-24.14%	-11.54%
Operating Cash Flow Q/Q Growth	16.81%	30.62%	-13.76%	-4.08%	3.28%	10.23%	7.18%	-7.32%	-30.30%	-12.05%
Free Cash Flow Firm Q/Q Growth	-3.08%	39.91%	-18.45%	7.49%	-30.33%	-44.04%	13.65%	48.08%	1.60%	9.65%
Invested Capital Q/Q Growth	-18.77%	-12.87%	12.85%	2.50%	-25.19%	16.97%	1.97%	-8.16%	-17.48%	-11.53%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	-279,295.45%	-431,547.62%	-295,090.91%	-360,759.09%	-321,536.67%	-108,221.05%	0.00%
Operating Margin	0.00%	0.00%	0.00%	-315,927.27%	-405,280.95%	-286,345.45%	-366,090.91%	-330,306.67%	-101,537.89%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	-295,454.55%	-448,104.76%	-311,327.27%	-377,318.18%	-333,226.67%	-111,450.53%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	-295,454.55%	-408,466.67%	-283,122.73%	-360,145.45%	-333,226.67%	-108,030.53%	0.00%
Tax Burden Percent	100.74%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	87.66%	90.94%	93.01%	100.00%	91.15%	90.94%	95.45%	100.00%	96.93%	98.81%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	-299.43%	-405.33%	-401.74%	-446.94%	-330.29%	-139.81%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	-295.89%	-400.32%	-398.59%	-443.30%	-325.48%	-134.91%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	259.80%	355.17%	347.78%	390.86%	286.13%	121.47%	0.00%
Return on Equity (ROE)	0.00%	0.00%	0.00%	-39.62%	-50.16%	-53.96%	-56.08%	-44.16%	-18.34%	0.00%
Cash Return on Invested Capital (CROIC)	-331.21%	-268.86%	-295.02%	-315.87%	-325.17%	-271.40%	-260.22%	-237.12%	-280.49%	-183.80%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	-38.56%	-58.14%	-65.77%	-64.55%	-48.67%	-18.57%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	-38.56%	-53.00%	-59.81%	-61.61%	-48.67%	-18.00%	0.00%
Return on Common Equity (ROCE)	0.00%	0.00%	0.00%	-39.62%	-50.16%	-53.96%	-56.08%	-44.16%	-18.34%	0.00%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-61.12%	-54.25%	-63.35%	0.00%	-59.01%	-58.59%	-60.87%	0.00%	-32.12%
Net Operating Profit after Tax (NOPAT)	-42	-50	-50	-49	-60	-44	-56	-69	-68	-58
NOPAT Margin	0.00%	0.00%	0.00%	-221,149.09%	-283,696.67%	-200,441.82%	-256,263.64%	-231,214.67%	-71,076.53%	0.00%
Net Nonoperating Expense Percent (NNEP)	-4.26%	-3.54%	-3.27%	-3.53%	-5.01%	-3.15%	-3.64%	-4.81%	-4.90%	-3.32%
Return On Investment Capital (ROIC_SIMPLE)	-10.03%	-	-	-	-11.63%	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	78,486.36%	82,019.05%	77,459.09%	84,200.00%	62,946.67%	22,107.37%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	237,540.91%	260,290.48%	208,986.36%	281,990.91%	267,460.00%	79,388.42%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	316,027.27%	405,380.95%	286,445.45%	366,190.91%	330,406.67%	101,495.79%	0.00%
Earnings before Interest and Taxes (EBIT)	-68	-73	-71	-65	-94	-68	-83	-100	-106	-84
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-65	-70	-68	-61	-91	-65	-79	-96	-103	-80
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.06	1.26	0.77	1.64	1.05	0.91	1.16	1.21	1.36	2.10
Price to Tangible Book Value (P/TBV)	1.06	1.26	0.77	1.64	1.05	0.91	1.16	1.21	1.36	2.10
Price to Revenue (P/Rev)	20,300.07	13,616.56	6,124.44	8,687.83	5,685.98	3,144.23	4,930.84	5,710.54	5,814.63	20.49
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.50	3.02	0.00	5.80	1.47	0.35	2.49	2.81	4.29	10.18
Enterprise Value to Revenue (EV/Rev)	3,338.75	4,235.52	0.00	4,090.35	924.49	167.67	1,159.01	1,509.45	2,008.29	11.90
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.88	-0.87	-0.88	-0.88	-0.89	-0.87	-0.88	-0.88	-0.90	-0.90
Leverage Ratio	1.28	1.24	1.25	1.27	1.24	1.21	1.21	1.18	1.18	1.15
Compound Leverage Factor	1.12	1.13	1.16	1.27	1.13	1.10	1.15	1.18	1.14	1.14
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-2.35	-1.23	-1.44	0.12	-0.62	-0.01	0.71	0.50	1.68	4.99
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	8.54	9.35	12.25	12.80	12.38	12.58	9.18	8.08	9.84	11.64
Quick Ratio	8.23	8.95	11.92	12.46	12.10	12.37	8.99	7.91	9.63	11.30
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-31	-31	-51	-43	-46	-36	-25	-29	-55	-56
Operating Cash Flow to CapEx	-14,279.38%	-10,283.22%	0.00%	-698,737.50%	-29,672.38%	-462,750.00%	-21,478.13%	-6,438.55%	-3,669.98%	-21,369.96%
Free Cash Flow to Firm to Interest Expense	0.00	-305.43	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	-441.15	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	-445.44	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.08
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.63
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	49	60	69	61	60	80	68	67	73	89
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.85
Increase / (Decrease) in Invested Capital	-11	-20	0.83	-5.74	-13	-8.52	-32	-41	-12	-1.75
Enterprise Value (EV)	73	182	-48	356	88	28	170	189	313	902
Market Capitalization	447	586	398	756	540	531	725	714	907	1,553
Book Value per Share	$2.01	$2.22	$3.01	$2.73	$3.04	$3.48	$4.27	$4.10	$4.62	$5.15
Tangible Book Value per Share	$2.01	$2.22	$3.01	$2.73	$3.04	$3.48	$4.27	$4.10	$4.62	$5.15
Total Capital	422	464	515	461	512	583	623	592	667	740
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-373	-403	-446	-400	-452	-503	-554	-525	-594	-651
Capital Expenditures (CapEx)	0.26	0.43	0.00	0.01	0.18	0.01	0.29	1.04	1.69	0.22
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-25	-20	-25	-20	-27	-30	-45	-49	-42	-32
Debt-free Net Working Capital (DFNWC)	268	272	420	364	422	436	447	422	475	520
Net Working Capital (NWC)	268	272	420	364	422	436	447	422	475	520
Net Nonoperating Expense (NNE)	18	16	16	16	26	18	23	31	35	25
Net Nonoperating Obligations (NNO)	-373	-403	-446	-400	-452	-503	-554	-525	-594	-651
Total Depreciation and Amortization (D&A)	3.23	3.21	3.64	3.56	3.48	3.57	3.64	3.51	3.07	3.86
Debt-free, Cash-free Net Working Capital to Revenue	-111,877.27%	-45,860.47%	-38,167.69%	-23,436.78%	-28,064.21%	-17,566.27%	-30,327.89%	-39,475.20%	-27,066.67%	-42.27%
Debt-free Net Working Capital to Revenue	1,217,559.09%	632,195.35%	645,875.38%	418,931.03%	444,248.42%	257,880.47%	304,340.14%	337,504.00%	304,548.72%	686.22%
Net Working Capital to Revenue	1,217,559.09%	632,195.35%	645,875.38%	418,931.03%	444,248.42%	257,880.47%	304,340.14%	337,504.00%	304,548.72%	686.22%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.27)	($0.32)	($0.35)	($0.38)	($0.49)	($0.37)	($0.53)	($0.68)	($0.72)	($0.58)
Adjusted Weighted Average Basic Shares Outstanding	194.81M	209.19M	190.03M	169.13M	156.93M	167.65M	146.80M	144.56M	143.15M	143.66M
Adjusted Diluted Earnings per Share	($0.27)	($0.32)	($0.35)	($0.38)	($0.49)	($0.37)	($0.53)	($0.68)	($0.72)	($0.58)
Adjusted Weighted Average Diluted Shares Outstanding	194.81M	209.19M	190.03M	169.13M	156.93M	167.65M	146.80M	144.56M	143.15M	143.66M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	217.26M	209.67M	209.11M	170.85M	169.09M	168.28M	167.63M	145.84M	144.50M	144.21M
Normalized Net Operating Profit after Tax (NOPAT)	-42	-43	-47	-49	-60	-44	-56	-69	-68	-58
Normalized NOPAT Margin	0.00%	0.00%	0.00%	-221,149.09%	-283,696.67%	-200,441.82%	-256,263.64%	-231,214.67%	-71,076.53%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	-295,454.55%	-408,466.67%	-283,122.73%	-360,145.45%	-333,226.67%	-108,030.53%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-728.98	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	-502.42	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	-733.27	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	-506.71	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Allogene Therapeutics' Financials

When does Allogene Therapeutics's financial year end?

According to the most recent income statement we have on file, Allogene Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Allogene Therapeutics' net income changed over the last 2 years?

Allogene Therapeutics' net income appears to be on a downward trend, with a most recent value of -$257.59 million in 2024, falling from -$340.41 million in 2022. The previous period was -$327.27 million in 2023. Check out Allogene Therapeutics' forecast to explore projected trends and price targets.

What is Allogene Therapeutics's operating income?

Allogene Therapeutics's total operating income in 2024 was -$273.20 million, based on the following breakdown:

Total Gross Profit: $22 thousand
Total Operating Expenses: $273.22 million

How has Allogene Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Allogene Therapeutics' total revenue changed from $156 thousand in 2022 to $22 thousand in 2024, a change of -85.9%.

How much debt does Allogene Therapeutics have?

Allogene Therapeutics' total liabilities were at $126.53 million at the end of 2024, a 3.1% decrease from 2023, and a 18.2% decrease since 2022.

How much cash does Allogene Therapeutics have?

In the past 2 years, Allogene Therapeutics' cash and equivalents has ranged from $61.90 million in 2022 to $83.16 million in 2023, and is currently $75.22 million as of their latest financial filing in 2024.

How has Allogene Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Allogene Therapeutics' book value per share changed from 4.62 in 2022 to 2.01 in 2024, a change of -56.5%.

Related Companies

This page (NASDAQ:ALLO) was last updated on 5/29/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Allogene Therapeutics (ALLO) Financials

Frequently Asked Questions About Allogene Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Allogene Therapeutics (ALLO) Financials

Annual Income Statements for Allogene Therapeutics

Quarterly Income Statements for Allogene Therapeutics

Annual Cash Flow Statements for Allogene Therapeutics

Quarterly Cash Flow Statements for Allogene Therapeutics

Annual Balance Sheets for Allogene Therapeutics

Quarterly Balance Sheets for Allogene Therapeutics

Annual Metrics And Ratios for Allogene Therapeutics

Quarterly Metrics And Ratios for Allogene Therapeutics

Frequently Asked Questions About Allogene Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools